Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05498181 · ClinicalTrials.gov registry record · Phase 2
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
A Phase 2 study of Hemodialysis, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05498181 is a Phase 2 study of Hemodialysis that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 100 participants, below the 131-participant average among 12 other Hemodialysis trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05498181, a Phase 2 study of Hemodialysis, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized placebo-controlled clinical trial will evaluate the effect of sacubitril/valsartan (compared with placebo) on echocardiographic measures of hypervolemia, preservation of residual renal function, and key safety parameters in incident hemodialysis patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sacubitril-valsartan
Study Locations (1)
Massachusetts
- Brigham and Women's - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-10-11 |
| Est. Completion | 2026-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05498181
The ClinicalTrials.gov registry entry for NCT05498181 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 12 other Hemodialysis trials with a reported enrollment target (24% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemodialysis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05498181 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05498181 about?
NCT05498181 is a clinical study titled "Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation". This randomized placebo-controlled clinical trial will evaluate the effect of sacubitril/valsartan (compared with placebo) on echocardiographic measures of hypervolemia, preservation of residual renal function, and key safety parameters in incident hemodialysis patients.
What is the current status of trial NCT05498181?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2022-10-11. Estimated completion is 2026-07-30.
What conditions does trial NCT05498181 study?
This clinical trial studies the following conditions: Hemodialysis.
What interventions are being tested in trial NCT05498181?
The interventions under investigation include: Placebo (DRUG), Sacubitril-valsartan (DRUG).
Who is sponsoring clinical trial NCT05498181?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05498181 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemodialysis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Physical Activity Prescription Program for Hemodialysis Patients
RECRUITING · NA
-
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
RECRUITING · NA
-
Contactless Optical Monitoring of AV Access Using the PatenSee System in Outpatient Hemodialysis Patients
RECRUITING
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
RECRUITING · NA
-
Trial to Evaluate and Assess the Effect of Comprehensive Pre-ESKD Education on Home Dialysis Use in Veterans
ACTIVE NOT RECRUITING · NA
-
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.